At the same meeting, Immunomedics Inc. (NASDAQ:IMMU) reported clinical results of itsinfectious disease imaging agent, ImmuRAID-MN3, a technetium-99m conjugate of a monoclonalantibody fragment. The compound, in Phase III studies, seeks out infection-fightinggranulocytes that are visualized with a nuclear medicine camera.
ImmuRAID-MN3 accurately detected inflammation in 10 patients with known infections in astudy at Our Lady of the Lake Regional Medical Center in Baton Rouge, La., and identifiedosteomyelitis and soft tissue infections with better than 80 percent accuracy in 20patients with suspected infections studied at the University Erlangen-Nuremberg, Germany.
The agent concentrated at the infection site within about an hour of injection, and nopatients developed human anti-mouse antibody (HAMA) reactions or other adverse responses,company representatives said.
Immunomedics of Morris Plains, N.J., also reported that a second injection of itsImmuRAID-CEA in 18 colorectal cancer patients did not produce a HAMA reaction. This agentis under review for marketing approval in the U.S., Europe and Canada.